The matrix metalloproteinase inhibitor RS-130830 attenuates brain injury in experimental pneumococcal meningitis

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Liechti, Fabian D ^a   Bächtold, Fabian ^a   Grandgirard, Denis ^a   Leppert, David ^b   Leib, Stephen L ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c SPIEZ LABORATORY   (Switzerland)

Author keywords

Bacterial meningitis; Matrix metalloproteinases; MMP inhibitor; Neuroinfection; Streptococcus pneumoniae

Indexed keywords

4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; CEFTRIAXONE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; TUMOR NECROSIS FACTOR; CYTOKINE; ENZYME INHIBITOR; HYDROXAMIC ACID; RS-130830;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN INJURY; CEREBROSPINAL FLUID LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INHIBITION; HISTOPATHOLOGY; INFANT; LEUKOCYTE COUNT; NONHUMAN; PNEUMOCOCCAL MENINGITIS; RAT; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE; TREATMENT RESPONSE; WEIGHT REDUCTION; ANIMAL; BRAIN INJURIES; COMPLICATION; DISEASE MODEL; LEUKOCYTE; METABOLISM; MICROBIOLOGY; NEWBORN; PATHOLOGY; WISTAR RAT;

ANIMALS; ANIMALS, NEWBORN; BRAIN INJURIES; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HYDROXAMIC ACIDS; LEUKOCYTES; MENINGITIS, PNEUMOCOCCAL; RATS; RATS, WISTAR;

EID: 84928752510     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0257-0     Document Type: Article

References (24)

1. Agyeman P, Grandgirard D, Leib S. Pathogenesis and Pathophysiology of Bacterial Infections. In: Scheld MW, Whitley RJ, Marra CM, editors. Infections of the Central Nervous System. 4th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2014.
2. Koedel U, Scheld WM, Pfister HW. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis. 2002;2:721-36.
3. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia. 2002;39:279-91.
4. Paul R, Lorenzl S, Koedel U, Sporer B, Vogel U, Frosch M, et al. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann Neurol. 1998;44:592-600.
5. Leppert D, Leib SL, Grygar C, Miller KM, Schaad UB, Hollander GA. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clin Infect Dis. 2000;31:80-4.
6. van Furth AM, Roord JJ, van Furth R. Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy. Infect Immun. 1996;64:4883-90.
7. Grandgirard D, Burri M, Agyeman P, Leib SL. Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis. Antimicrob Agents Chemother. 2012;56:4289-95.
8. Baranger K, Rivera S, Liechti FD, Grandgirard D, Bigas J, Seco J, et al. Endogenous and synthetic MMP inhibitors in CNS physiopathology. Prog Brain Res. 2014;214:313-51.
9. Whittaker M, Floyd CD, Brown P, Gearing AJ. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev. 1999;99:2735-76.
10. Close DR. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis. 2001;60 Suppl 3:iii62-7.
11. Lovejoy B, Welch AR, Carr S, Luong C, Broka C, Hendricks RT, et al. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat Struct Biol. 1999;6:217-21.
12. Becker DP, Villamil CI, Barta TE, Bedell LJ, Boehm TL, Decrescenzo GA, et al. Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy. J Med Chem. 2005;48:6713-30.
13. Kahraman A, Bronk SF, Cazanave S, Werneburg NW, Mott JL, Contreras PC, et al. Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse. Hepatol Res. 2009;39:805-13.
14. Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A, et al. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J Med Chem. 2003;46:2376-96.
15. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2013;6, CD004405.
16. Leib SL, Leppert D, Clements J, Tauber MG. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun. 2000;68:615-20.
17. Leib SL, Clements JM, Lindberg RL, Heimgartner C, Loeffler JM, Pfister LA, et al. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain. 2001;124:1734-42.
18. Meli DN, Loeffler JM, Baumann P, Neumann U, Buhl T, Leppert D, et al. In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-alpha converting enzyme attenuates seizures and injury of the cerebral cortex. J Neuroimmunol. 2004;151:6-11.
19. Meli DN, Coimbra RS, Erhart DG, Loquet G, Bellac CL, Tauber MG, et al. Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis. Infect Immun. 2006;74:3890-6.
20. Janser P, Neumann U, Miltz W, Feifel R, Buhl T. A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg Med Chem Lett. 2006;16:2632-6.
21. Mook-Kanamori BB, GeldhoffM, van der Poll T, van de Beek D. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev. 2011;24:557-91.
22. Tuomanen EI, Saukkonen K, Sande S, Cioffe C, Wright SD. Reduction of inflammation, tissue damage, and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes. J Exp Med. 1989;170:959-69.
23. Snoek-van Beurden PA, Von Den HoffJW. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. BioTechniques. 2005;38:73-83.
24. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001;2:502-11.